Arbutus Biopharma
ABUS
4.29
-0.19
-4.24%
Arbutus Biopharma
US · ABUS
#3365 by market cap
Listed 2015
4.29
-0.19
-4.24%
Live - 5344 symbols - heartbeat 196s ago
· 2026-10-08 08:32
Pre-market
4.35
+1.31%
After-hours
4.30
+0.23%
- Market cap
- 849.87M
- P/E (TTM)i
- 5.43
- P/Bi
- 3.28
- EPSi
- -0.17
- Div yieldi
- 0.00%
- 52W posi
- 41%
Reader sentiment
Are you bullish or bearish on ABUS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.1 percentage points.
Institutional ownership
- Held by institutions
- 87.03% -4.09pp
- Institutions
- 204 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund36.01%
Hedge Fund26.44%
Public Company19.97%
Private Company3.23%
Individual/Insider0.88%
Family Office/Trust0.78%
Government Pension Fund0.44%
Insurance Company0.16%
Other12.08%
Top holders as of 2026-10-01
Roivant Sciences Ltd.
15.10% · 29.88M sh
Two Seas Capital LP
9.65% · 19.10M sh
Morgan Stanley Investment Management Inc.
8.65% · 17.12M sh
Whitefort Capital Management, LP
7.98% · 15.79M sh
BlackRock
6.96% · 13.77M sh
Vanguard Capital Management, LLC
4.12% · 8.15M sh
State Street Global Advisors
3.98% · 7.87M sh
Rubric Capital Management LP
3.81% · 7.53M sh
Geode Capital Management, LLC
2.08% · 4.12M sh
Barclays Bank Plc
2.07% · 4.10M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Roivant Sciences Ltd. | -- | 15.10% |
| Michael McElhaugh | COO & Chief Business Officer | 0.69% |
| Tuan Nguyen | Chief Financial Officer | 0.08% |
| Lindsay Androski | Interim President, CEO & Director | 0.04% |
| David Hastings | Chief Financial Officer | 0.03% |
| Robert Beardsley | Director | 0.02% |
| Roger Sawhney | Director | 0.02% |
| J. Naftzger | Chief Compliance Officer | 0.01% |
| Michael Sofia | Chief Scientific Officer | -- |
| Karen Sims | Chief Medical Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Roivant Sciences Ltd. | -- | Sale to Issuer | -8,967,383 | $5.00 |
| 2026-09-17 | Robert Beardsley | Director | Derivative Exercise and Sale | -99,057 | $3.20–5.07 |
| 2026-09-17 | Robert Beardsley | Director | Derivative Exercise and Retained | +32,276 | $3.20 |
| 2026-09-17 | Roger Sawhney | Director | Derivative Exercise and Sale | -100,508 | $3.34–5.07 |
| 2026-09-17 | Roger Sawhney | Director | Derivative Exercise and Retained | +30,825 | $3.34 |
| 2026-09-17 | Lindsay Androski | Interim President, CEO & Director | Derivative Exercise and Sale | -82,527 | $3.20–5.07 |
| 2026-09-17 | Lindsay Androski | Interim President, CEO & Director | Derivative Exercise and Retained | +44,337 | $3.20 |
| 2026-09-17 | Tuan Nguyen | Chief Financial Officer | Derivative Exercise and Sale | -206,637 | $3.49–5.07 |
| 2026-09-17 | Tuan Nguyen | Chief Financial Officer | Derivative Exercise and Retained | +86,463 | $3.49 |
| 2026-06-07 | Robert Beardsley | Director | Other Derivative Acquisition | +78,800 | $4.24 |
| 2026-06-07 | Roger Sawhney | Director | Other Derivative Acquisition | +78,800 | $4.24 |
| 2026-02-01 | Lindsay Androski | Interim President, CEO & Director | Other Acquisition | +28,000 | -- |
| 2026-02-01 | Lindsay Androski | Interim President, CEO & Director | Other Derivative Acquisition | +71,700 | $4.39 |
| 2026-02-01 | Tuan Nguyen | Chief Financial Officer | Other Acquisition | +73,500 | -- |
| 2026-02-01 | Tuan Nguyen | Chief Financial Officer | Other Derivative Acquisition | +188,400 | $4.39 |
| 2025-08-03 | Roger Sawhney | Director | Other Derivative Acquisition | +157,600 | $3.34 |
| 2025-04-20 | Michael McElhaugh | COO & Chief Business Officer | Intent to Sell (Form 144) | -246,886 | $3.26 |
| 2025-04-14 | Michael McElhaugh | COO & Chief Business Officer | Intent to Sell (Form 144) | -53,114 | $3.20 |
| 2025-03-30 | Michael Sofia | Chief Scientific Officer | Intent to Sell (Form 144) | -250,000 | $3.50 |
| 2025-03-30 | Tuan Nguyen | Chief Financial Officer | Other Derivative Acquisition | +750,000 | $3.49 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:32:55 · For reference only, not investment advice and not tailored to your situation.